Related Experiment Video
Updated: Apr 3, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
[Regulatory aspects of biosimilars. Myths and facts]
C K Schneider1,2,3, M Weise4,5
1Abteilung Arzneimittelzulassung und -Zugänglichkeit, Danish Health and Medicines Authority, Axel Heides Gade 1, 2300, Kopenhagen, Dänemark. ckschneider@gmx.de.
Background:
Biosimilars are currently a hot topic and there are many unsolved questions, misunderstandings and sometimes considerable uncertainty, especially among clinicians and patients. Regulatory agencies, such as the European Medicines Agency (EMA) issue guidelines for the development and approval of biosimilars, which are based on scientific principles.
Objective:
This article addresses some of the frequently noted misunderstandings and misperceptions. For example, why biosimilars are (or can only be) "similar" but not "identical" compared to the original pharmaceutical product, and aspects, such as the pharmaceutical quality of biosimilars, immunogenicity and the approval process for biosimilars are highlighted.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Drug Regulation
Bioequivalence: Overview
Drug Control Governance: Regulatory Bodies and Their Impact
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

